ARXX Therapeutics ApS: Financial statements 2022
CVR: 40868151
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ARXX Therapeutics ApS (CVR 40868151) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 5,789,922 and a net result of DKK 507,105 compared with DKK 77,355 the year before. That is an increase of 141.6% compared with the year before. The profit margin was 8.8%. Equity in the 2022 report amounted to DKK 595,721. The solvency ratio was 50.8%.
- Revenue
- DKK 5,789,922
- Gross Profit
- DKK 2,223,100
- Profit/Loss
- DKK 507,105
- Equity
- DKK 595,721
- Total Assets
- DKK 1,173,010
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 5.8M | 2.2M | 507K | 596K | - |
| 2021 | 2.4M | 1.7M | 77K | 177K | - |
Official annual report
Keep an eye on ARXX Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ARXX Therapeutics ApS has published its annual report for 2021. Revenue came to DKK 2,396,646, and the net result was DKK 77,355.
About ARXX Therapeutics ApS
ARXX Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Berte Aagot Hedding Poulsson and Jonas Hallén. The company is owned by ARXX THERAPEUTICS AS. The company has 2 employees (2026). In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. Equity in the 2025 report amounted to DKK 1,688,804.